Scientifically reviewed by Dr Stephan Hansberg
Is BPC-157 legal? US, UK and Australia status (2026)
The legal status of BPC-157 in the US, UK and Australia as of October 2026: the FDA's Category 2 history and July 2026 advisory vote, UK medicines law, Australia's Schedule 4 listing, and its WADA S0 status.
Key takeaways
- •BPC-157 is not an approved medicine anywhere; WADA names it as an example of an S0 non-approved substance.
- •US: off the FDA's Category 2 list since April 2026 and recommended for the 503A bulks list by an advisory committee in July 2026, but not yet on that list.
- •UK: not a controlled drug; it becomes a regulated medicine when presented or used as one, and the MHRA acted on clinic claims in 2026.
- •Australia: Schedule 4 and Appendix D since 1 June 2024, so possession without authority is an offence.
- •Sport: prohibited at all times under S0 since 2022, and named on the NCAA's 2026-27 banned list.
The short answer
BPC-157 is not an approved medicine in the US, UK or Australia, and its legal status depends on the country and on how it is sold. In the US and UK it is not a controlled drug, so the legal risk sits mainly with selling or presenting it for human use, while in Australia it is a Schedule 4 substance that is illegal to possess without authority.
BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a fragment of a protein found in gastric juice. It has been studied mainly in rodent models for gastrointestinal and tissue research, with very limited human data. None of that research changes its legal classification.
BPC-157 status at a glance (October 2026)
| Jurisdiction | Regulator | Status | Most recent change |
|---|---|---|---|
| United States | FDA | Not FDA-approved; not a controlled substance; not on the 503A bulks list | PCAC recommended bulks list inclusion, 23 Jul 2026 (8-6, 1 abstention); rulemaking pending |
| United Kingdom | MHRA | Not a licensed medicine; not a controlled drug; treated as a medicine if presented or used as one | MHRA looked into clinic claims, Apr 2026 |
| Australia | TGA | Schedule 4 (prescription only) and Appendix D: possession without authority is illegal | Named in TGA compliance priority, Jun 2026 |
| Sport (WADA) | WADA | S0 non-approved substance, prohibited at all times, Specified Substance | Named in S0 since the 2022 List |
United States
The FDA placed BPC-157 in Category 2 of its 503A bulk substances list on 29 September 2023, citing a possible risk of immunogenicity for some routes of administration, complexities with peptide-related impurities, and limited safety information. Category 2 meant pharmacies should not compound it.
On 22 April 2026 BPC-157 was moved off Category 2 because its nominators withdrew their nominations. That did not put it on the bulks list. On 23 July 2026 the Pharmacy Compounding Advisory Committee, which reviewed BPC-157 free base and BPC-157 acetate for ulcerative colitis, voted 8-6 with one abstention to recommend adding both to the bulks list. The FDA's own briefing document had proposed not adding it.
Advisory votes are not binding. The FDA must decide and then complete notice-and-comment rulemaking before BPC-157 can be lawfully compounded under 503A, and as of October 2026 that had not happened. BPC-157 is not scheduled under the Controlled Substances Act. The FDA has issued warning letters where sellers labelled products for research while their websites showed they were intended for people.
United Kingdom
BPC-157 is not a controlled drug under the Misuse of Drugs Act 1971 and it holds no UK marketing authorisation. Under the Human Medicines Regulations 2012, a product is a medicine if it is presented as treating or preventing disease or is used to modify physiological function, and a medicine needs a marketing authorisation before it can be sold or supplied for that purpose.
In April 2026 the MHRA said that clinics offering peptide injections with medicinal claims would have those products treated as medicines. A clinic website reviewed by The Guardian described BPC-157 as aiding tissue repair; the MHRA said that was a medicinal claim, and the wording was removed. For a laboratory supplier, the practical line is the same: research use only labelling must be matched by research use only presentation.
Australia
Australia is the strictest of the three. The TGA's scheduling delegate added BPC-157 to Schedule 4 of the Poisons Standard and to Appendix D, clause 5, which lists poisons for which possession without authority is illegal, with effect from 1 June 2024. The decision followed 48 referrals for BPC-157 importation received since 1 July 2022 and aligned it with other performance and image enhancing substances.
In June 2026 the TGA named BPC-157 among the unapproved peptides in its compliance priority. In August 2026 it seized products, including a BPC-157 and TB-500 combination, from premises linked to a social media influencer, and in September 2026 it started Federal Court proceedings against BioV8 over alleged advertising of peptides including BPC-157. A research use only label on a parcel does not change how Australian law treats an imported Schedule 4 substance.
Sport: WADA and NCAA
BPC-157 is named on the WADA Prohibited List as an example in S0, non-approved substances, which covers any pharmacological substance without approval by any government health authority for human therapeutic use. It has been named since the 2022 List and is prohibited in and out of competition. S0 substances are Specified Substances, which affects sanction ranges, not whether use is allowed. USADA says a Therapeutic Use Exemption for BPC-157 is unlikely to be granted.
The NCAA's 2026-27 banned substances list names BPC-157 among its peptide hormone and growth factor examples. See our guide to peptides in sport for the wider picture.
Where Celyfe fits
Celyfe supplies BPC-157 only as a component of pre-filled 3 ml research pens: WOLVERINE (BPC-157 15 mg and TB-500 15 mg), GLOW (GHK-Cu 75 mg, BPC-157 15 mg and TB-500 15 mg) and KLOW (GLOW plus KPV 15 mg). WOLVERINE batch C26071 was tested by HPLC at 99% purity by the independent laboratory Analiza Bialek in Wroclaw, Poland, in a report dated 2 October 2026. GLOW and KLOW certificates are listed in the Celyfe COA library when published.
These pens are sold for laboratory research. Buyers are responsible for complying with the law where they are, and in Australia that includes Schedule 4 and Appendix D.
Sources
Checked 8 October 2026:
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157 entry dated 29 Sep 2023; current page as of 22 Apr 2026), fda.gov
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee, and briefing document on BPC-157, fda.gov
- The FDA Law Blog: PCAC approves four bulk drug substances for the 503A list, 24 Jul 2026
- TGA: Notice of final decisions to amend (or not amend) the current Poisons Standard, November 2023 meetings, published 22 May 2024 (BPC-157, implementation 1 Jun 2024), tga.gov.au
- TGA media releases on unapproved peptides, 10 Jun, 19 Jun, Aug and 28 Sep 2026, tga.gov.au
- The Guardian: Medicines watchdog to investigate UK peptide clinics over health claims, 4 Apr 2026
- WADA: Prohibited List 2026 (S0), wada-ama.org
- USADA: BPC-157: Experimental peptide creates risk for athletes, usada.org
- NCAA: 2026-27 banned substances list, ncaa.org
Research use only
Celyfe supplies research peptides for laboratory and research use only. Nothing on this page is guidance on use in humans or animals. This is general information, not legal advice. Rules in all three countries changed several times in 2026, so check the regulator's current publications or speak to a qualified adviser before relying on anything here.
Regulation alerts
Get notified when the rules change
We email when FDA, MHRA, TGA or WADA status changes for the compounds we cover, with the source linked. No spam, unsubscribe at any time.